Corvus Pharmaceuticals (CRVS) Falls on Profit-Taking After 212% Jump

We recently published 10 Big Names Stumbling Hard. Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) was one of the worst performers on Monday.

Corvus Pharmaceuticals dropped by 8.33 percent on Monday to finish at $23.01 apiece as investors resorted to profit-taking after soaring by 212 percent in last week’s shortened trading.

Last week’s rally followed strong results from the clinical trial of its drug candidate, soquelitinib, in patients with moderate to severe eczema.

In an updated report, Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) said that its drug candidate successfully demonstrated a 72 percent reduction in the severity of enrolled patients’ eczema in the first phase trial, as compared with the 40 percent reduction for those who took the placebo.

Additionally, the therapy was observed to be even more effective when taken longer, and it was well-tolerated by enrolled patients.

Based on the positive results, Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) is planning to initiate a Phase 2 trial in the first quarter of 2026 and enroll 200 patients with moderate-to-severe atopic dermatitis who have failed at least one prior topical or systemic therapy.

The trial is anticipated to enroll four cohorts of 50 patients each, with soquelitinib doses of 200 mg once per day, 200 mg twice per day, and 400 mg once per day, along with a placebo group.

The Phase 2 trial is targeted to run for 12 weeks with a 30-day follow-up period without treatment.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.